Home >> Tag Archives: DiaSorin—

Tag Archives: DiaSorin—

DiaSorin gets FDA clearance for PCT assay

April 6, 2018—DiaSorin received clearance from the Food and Drug Administration to market the Liaison Brahms PCT II Gen assay for the quantitative determination of procalcitonin. “I am pleased to announce the addition of the Brahms PCT II Gen assay to our growing specialty menu in the U.S. market”, John Walter, president of DiaSorin, said in a statement. “I’m proud ...

Read More »

Qiagen, DiaSorin partnership, 2/18

February 2018—Qiagen and DiaSorin announced a partnership in which Qiagen’s QuantiFeron-TB diagnostic test will be added to the menu of DiaSorin’s Liaison family of analyzers, enabling customers of both companies to process QuantiFeron-TB Gold Plus, a fourth-generation assay for latent tuberculosis detection, on Liaison platforms. QFT-Plus is the first assay from the QuantiFeron portfolio that is planned to be adapted for use on the Liaison systems, with additional assays under consideration.

Read More »

Emergency use authorization for Zika IgM test

April 24, 2017—DiaSorin has received FDA emergency use authorization for the Liaison XL Zika Capture IgM assay, a fully automated serology assay for the detection of Zika virus infections. “Leveraging over 40 years of infectious disease immunoassay product development and commercialization, we were able to develop a first-of-its-kind assay for Zika virus IgM detection,” John Walter, president of DiaSorin, said ...

Read More »

DiaSorin lands HHS grant for rapid Zika serology test

Sept. 6, 2016—The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has announced a $2.6 million agreement with DiaSorin Group to further develop a test that may help physicians determine more quickly whether a patient was infected recently with Zika virus. The automated laboratory test being developed by DiaSorin uses the company’s Liaison ...

Read More »

DiaSorin enters molecular market with Focus buy

April 7, 2016—DiaSorin will buy Quest’s Focus Diagnostics immunodiagnostic and molecular diagnostic products business for $300 million in cash. The deal includes all the tangible and intangible assets of Focus used to develop, manufacture, and distribute its molecular diagnostic products and its traditional immunoassay ELISA products, including relevant intellectual property, contracts, and customer list. Focus’ products include the Simplexa molecular ...

Read More »

FDA clearance for parathyroid hormone assay, 7/14

July 2014—DiaSorin received FDA clearance for its Liaison N-Tact PTH Gen II immunoassay, intended for the quantitative determination of intact human parathyroid hormone in human serum and plasma samples. The kit contains 200 tests and has an open-kit shelf life of 8 weeks, meeting the needs of small- and large-volume laboratories. It also has low cross-reactivity to the 7-84 and other inactive fragments, supporting conservative patient management.

Read More »

IGF-1 assay, 7/13:108

DiaSorin’s Liaison IGF-1 assay is a solution for full automation of growth factor testing on a random-access analyzer, for accurately monitoring growth dysfunctions. The company offers an extensive menu of reliable, fully automated chemiluminescent assays suitable for endocrinology clinics, reference laboratories, hospitals, and physician office laboratories. Patients benefit from rapid and accurate results, and laboratories benefit from fast turnaround time and ease of use with the Liaison assay product portfolio.

Read More »